Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

NCT00903292 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: erlotinib (Tarceva)
DRUG: pemetrexed (Alimta)

Sponsor

National Cheng-Kung University Hospital